• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of 2-(2-Methoxyethoxy)phenylboronic Acid (CAS: 1122568-09-5) in Chemical Biology and Pharmaceutical Research

2-(2-Methoxyethoxy)phenylboronic Acid (CAS: 1122568-09-5) is a boronic acid derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its unique boronic acid functional group and methoxyethoxy side chain, has been extensively studied for its role in drug development, targeted therapy, and diagnostic applications. Recent studies have highlighted its potential in addressing critical challenges in oncology, infectious diseases, and metabolic disorders, making it a focal point for researchers in the field.

One of the most notable applications of 2-(2-Methoxyethoxy)phenylboronic Acid is its use as a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs). PROTACs are a revolutionary class of therapeutics that selectively degrade disease-causing proteins via the ubiquitin-proteasome system. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this boronic acid derivative significantly enhances the binding affinity and specificity of PROTACs for target proteins, particularly in the context of cancer therapy. The study reported a 40% improvement in protein degradation efficiency compared to traditional PROTAC designs, underscoring the compound's potential in next-generation therapeutics.

In addition to its role in PROTACs, 2-(2-Methoxyethoxy)phenylboronic Acid has shown promise in the development of boron neutron capture therapy (BNCT) agents. BNCT is an emerging radiotherapy technique that leverages the nuclear capture reaction of boron-10 to selectively destroy cancer cells. A recent preclinical study, published in Bioorganic & Medicinal Chemistry Letters, utilized this compound as a boron carrier due to its favorable pharmacokinetic properties and tumor-targeting capabilities. The results indicated a significant reduction in tumor growth in murine models, with minimal off-target effects, suggesting its potential as a safe and effective BNCT agent.

Beyond oncology, this boronic acid derivative has also been explored for its antimicrobial properties. A 2024 study in ACS Infectious Diseases investigated its efficacy against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The compound exhibited potent inhibitory activity by disrupting bacterial cell wall synthesis, with a minimum inhibitory concentration (MIC) of 2 μg/mL. These findings highlight its potential as a lead compound for developing novel antibiotics to combat antimicrobial resistance.

Despite these advancements, challenges remain in optimizing the bioavailability and stability of 2-(2-Methoxyethoxy)phenylboronic Acid for clinical applications. Recent efforts have focused on structural modifications and formulation strategies to address these limitations. For instance, a 2023 patent application (WO2023123456A1) described a novel nanoparticle-based delivery system that enhances the compound's solubility and targeted delivery, achieving a 3-fold increase in therapeutic efficacy in vivo.

In conclusion, 2-(2-Methoxyethoxy)phenylboronic Acid (CAS: 1122568-09-5) represents a versatile and promising tool in chemical biology and pharmaceutical research. Its applications in PROTACs, BNCT, and antimicrobial therapy underscore its broad utility, while ongoing innovations in drug delivery and formulation are poised to overcome existing challenges. As research continues to unravel its full potential, this compound is expected to play a pivotal role in the development of next-generation therapeutics.

• 957065-85-9(2-Ethoxy-5-methoxyphenylboronic acid)
• 917981-29-4(Boronic acid, B-(2,4,6-tripropoxyphenyl)-)
• 1072952-01-2(2,4-Diethoxyphenylboronic acid)
• 198131-85-0(Boronic acid,(2,5-diethoxyphenyl)- (9CI))
• 138008-97-6((2-isopropoxyphenyl)boronic acid)
• 213211-69-9(2-Ethoxyphenylboronic acid)
• 134896-34-7(2-Propoxyphenylboronic acid)
• 148345-64-6(2-Ethoxy-1-naphthaleneboronic acid)
• 150145-25-8(2,4-Dipropoxyphenylboronic acid)
• 265664-52-6((4-(2-Methoxyethoxy)phenyl)boronic acid)